Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
A FEDERAL advisory committee this week will decide whether to recommend approval of the first in a new class of drugs that many experts believe could significantly cut the risk of strokes and heart attacks, a leading cause of death for Americans.
The highly anticipated